Personensuche
Personensuche
Es wurde 1 Person gefunden.
Aktuelle Veranstaltungen
-
WiSe 2025
Vergangene Veranstaltungen (max. 10)
-
SoSe 2025
-
WiSe 2024
-
SoSe 2024
-
WiSe 2023
-
SoSe 2023
-
WiSe 2022
-
SoSe 2022
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
Design, Synthesis, and SAR of Covalent KIT and PDGFRA Inhibitors─Exploring Their Potential in Targeting GISTIn: Journal of Medicinal Chemistry, Jg. 68, 2025, Nr. 3, S. 3238 – 3259
-
Avapritinib-based SAR studies unveil a binding pocket in KIT and PDGFRAIn: Nature Communications, Jg. 15, 2024, Nr. 1, 63DOI (Open Access)
-
KIT ATP-Binding Pocket/Activation Loop Mutations in GI Stromal Tumor : Emerging Mechanisms of Kinase Inhibitor EscapeIn: Journal of Clinical Oncology (JCO), Jg. 42, 2024, Nr. 12, S. 1439 – 1449
-
Reply to Y. Xia et al [Comprehensive Discussions on KIT ATP-Binding Pocket/Activation Loop Mutations in Ripretinib Resistance]In: Journal of Clinical Oncology (JCO), Jg. 42, 2024, Nr. 27, S. 3260 – 3261
-
Plasma Sequencing for Patients with GIST : Limitations and Opportunities in an Academic SettingIn: Cancers, Jg. 14, 2022, Nr. 22, 5496DOI (Open Access)
-
Resistance to avapritinib in pdgfra-driven gist is caused by secondary mutations in the pdgfra kinase domainIn: Cancer Discovery, Jg. 11, 2021, Nr. 1, S. 108 – 125
-
Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors (GISTs)In: Clinical Sarcoma Research, Jg. 9, 2019, 3DOI (Open Access)
-
Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797SIn: Chemical Science, Jg. 10, 2019, Nr. 46, S. 10789 – 10801DOI (Open Access)
-
KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors : TORC1/2 Inhibition as Salvage StrategyIn: Molecular Cancer Therapeutics, Jg. 18, 2019, Nr. 11, S. 1985 – 1996DOI (Open Access)
-
Indazole-Based covalent inhibitors to target drug-resistant epidermal growth factor receptorIn: Journal of Medicinal Chemistry, Jg. 60, 2017, Nr. 6, S. 2361 – 2372
-
Inhibitors to overcome secondary mutations in the stem cell factor receptor KITIn: Journal of Medicinal Chemistry, Jg. 60, 2017, Nr. 21, S. 8801 – 8815
-
Phase i study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumorsIn: British Journal of Cancer (BJC), Jg. 110, 2014, Nr. 5, S. 1155 – 1162DOI (Open Access)
-
Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growthIn: Proceedings of the National Academy of Sciences of the United States of America (PNAS), Jg. 110, 2013, Nr. 9, S. 3501 – 3506
-
DOG1 Regulates Growth and IGFBP5 in Gastrointestinal Stromal TumorsIn: Cancer Research, Jg. 73, 2013, Nr. 12, S. 3661 – 3670
-
IAP gene alterations and therapeutic modulation of IAPs by Smac mimetics in GIST
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 18.-22. Oktober 2013, Wien, Österreich,In: Onkologie, Jg. 36, 2013, Nr. Suppl. 7, S. 245 – 246 -
Secondary KIT mutations negatively impact cell growth in a novel isogenic model of imatinib-resistance in GIST
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 18.-22. Oktober 2013, Wien, Österreich,In: Onkologie, Jg. 36, 2013, Nr. Suppl. 7, S. 178 – 179 -
Inhibitors of Apoptosis Proteins (IAPs) in gastrointestinal stromal tumors - a therapeutic target?In: Onkologie, Jg. 35, 2012, Nr. Suppl. 6, S. 249
-
P53 modulation as a therapeutic strategy in gastrointestinal stromal tumorsIn: PLoS ONE, Jg. 7, 2012, Nr. 5DOI (Open Access)
-
Phase I trial of panobinostat (P) and imatinib (IM) in patients with treatment-refractory gastrointestinal stromal tumors (GIST)In: Journal of Clinical Oncology (JCO), Jg. 30, 2012, Nr. Suppl. 15, S. 10032
-
ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumourIn: The Journal of Pathology, Jg. 227, 2012, Nr. 2, S. 223 – 233
-
Effective therapeutic sensitization of gastrointestinal stromal tumors by a BH3 mimeticIn: European Journal of Cancer / EJC Supplements, Jg. 8, 2010, Nr. 7, S. 69 – 70
-
Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cellsIn: Cancer Research, Jg. 70, 2010, Nr. 1, S. 150 – 159
-
Therapeutic Potential of Mdm2 Inhibition in Malignant Germ Cell TumoursIn: European Urology, Jg. 57, 2010, Nr. 4, S. 679 – 687
-
Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumorsIn: Cancer Research, Jg. 69, 2009, Nr. 17, S. 6941 – 6950DOI (Open Access)
-
Role of PIK3CA as a predictive biomarker in metastatic, imatinib-resistant GIST : A ct-DNA substudy of the VOYAGER trial
ESMO Congress 2024, 13-17 September 2024, Barcelona, Spain,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 35, 2024, Nr. Suppl. 2, S. S1050 – S1051 -
Comprehensive profile of platelet derived growth factor receptor alpha (PDGFRA) mutations in gastrointestinal stromal tumors
Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, USA,In: Cancer Research. Philadelphia: American Association for Cancer Research (AACR), Jg. 80, 2020, Nr. 16: Supplement, S. 3005DOI (Open Access) -
Targeting the PI3K-and MAPK pathway in high grade leiomyosarcoma
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 28. September - 2. Oktober 2018, Wien,In: Oncology Research and Treatment. Basel: Karger, Jg. 41, 2018, Nr. Suppl. 4, S. 300DOI (Open Access) -
Effect of secondary KIT mutations on growth of GIST cells in the absence of selective pressure by imatinib in isogenic models of imatinib resistance
2014 ASCO Annual Meeting, 30 May to 3 June 2014, Chicago, Ill., USA,In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 32, 2014, Nr. 15, Suppl., 10555 -
Targeting glucose metabolism by 2-Deoxyglucose in Gastrointestinal Stromal Tumors
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 18.-22. Oktober 2013, Wien, Österreich,In: Onkologie. Basel: Karger, Jg. 36, 2013, Nr. Suppl. 7, S. 246 -
Inhibitors of apoptosis (IAPs) in gastrointestinal stromal tumorsIn: Cancer Research. Philadelphia: American Association for Cancer Research (AACR), Jg. 72, 2012, Nr. 8, Suppl., S. 3855 – 3855
-
Inhibition of the Ras/Raf/MAPK-pathway in GIST : Therapeutic potential?
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 30.09.–04.10. 2011, Basel, Switzerland,In: Onkologie. Basel: Karger, Jg. 34, 2011, Nr. Suppl. 6, S. 235 – 235 -
Evaluation of mismatch repair deficiency as predictive biomarker in novel sarcoma cell line models
Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 01.-04. Oktober 2021, Hybrid-Kongress,In: Oncology Research and Treatment. Basel: Karger, Jg. 44, 2021, Nr. Supplement 2, S. 186DOI (Open Access) -
The BH3-mimetic ABT-263 enhances the apoptotic response of GIST cells to KIT-inhibitory treatments
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 30.09.–04.10. 2011, Basel, Switzerland,In: Onkologie. Basel: Karger, Jg. 34, 2011, Nr. Suppl. 6, S. 254